Macrotech Developers IPO Subscribed 26% On First Day Of Issue
Macrotech Developers share sale via initial public offering (IPO) was subscribed 26 per cent on the first day of the issue, data from the National Stock Exchange showed. Macrotech Developers received 95,91,420 bids for 3,64,18,219 shares on offer. A total of 21,65,220 bids were received at the cut-off price, the data showed. The three-day share sale which began today will end on April 9.
Macrotech Developers, formerly known as Lodha Developers is planning to raise Rs 2,500 crore via IPO and is selling shares in the price band of Rs 483-486 per share. The shares are likely to be listed on the BSE and NSE on April 22, 2021.
Investors can bid for a minimum one lot of 30 shares, translating into the minimum application size of Rs 14,580 per lot at the higher end of the price band. The maximum application size per individual is 13 lots.
The company plans to use the IPO proceeds to pare its debt obligations and buy land for future growth.
The Macrotech IPO will be the largest property public issue after DLF, which went public in the year 2007. Its listed peers include DLF, Godrej Properties, Oberoi Realty, Sobha and Sunteck Realty.
Macrotech was founded by billionaire Mangal Prabhat Lodha in Mumbai. The company is primarily engaged in affordable residential real estate developments and in 2019, it entered into the development of logistics, industrial parks and commercial real estate. It is also known for luxury projects such as Trump Towers in Mumbai and Grosvenor Square in London.
ICICI Securities, Edelweiss Financial Services, IIFL Securities, JM Financial, YES Securities, SBI Capital Markets and BOB Capital Markets are the book running lead managers to the public issue, whereas Link Intime India is the registrar to the IPO.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.